The Senior VP of Finance of Loxo Oncology, Inc. (LOXO), Jennifer Burstein Sold 1,700 Shares of the Company; Profile of 8 Analysts Covering AMC Networks Inc. (AMCX)

February 15, 2018 - By Peter Kolinski

Based on an average share price of $93.2, Jennifer Burstein, the Loxo Oncology Inc’s Senior VP of Finance sold 1,700 shares of Loxo Oncology Inc worth close to $158,504 USD. She also sold 1,500 shares worth approximately $131,243 USD in the last month.

Among 24 analysts covering AMC Networks (NASDAQ:AMCX), 8 have Buy rating, 3 Sell and 13 Hold. Therefore 33% are positive. AMC Networks had 62 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Hold” rating by Loop Capital on Thursday, October 19. The firm has “Neutral” rating by Macquarie Research given on Tuesday, January 2. Jefferies maintained AMC Networks Inc. (NASDAQ:AMCX) rating on Thursday, November 2. Jefferies has “Hold” rating and $55.0 target. The rating was maintained by Stifel Nicolaus on Monday, December 19 with “Hold”. The firm has “Outperform” rating by FBR Capital given on Thursday, October 6. The firm has “Buy” rating by CLSA given on Monday, October 26. Evercore upgraded it to “Buy” rating and $90 target in Thursday, September 24 report. The stock of AMC Networks Inc. (NASDAQ:AMCX) earned “Hold” rating by Jefferies on Monday, July 10. Stifel Nicolaus maintained it with “Buy” rating and $70 target in Wednesday, July 20 report. KeyBanc Capital Markets maintained the shares of AMCX in report on Monday, October 16 with “Hold” rating. See AMC Networks Inc. (NASDAQ:AMCX) latest ratings:

05/02/2018 Broker: Cowen & Co Rating: Hold New Target: $63.0 Maintain
31/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $55 New Target: $57 Maintain
02/01/2018 Broker: Macquarie Research Old Rating: Outperform New Rating: Neutral Downgrade
03/11/2017 Broker: Loop Capital Rating: Hold Old Target: $60 New Target: $55 Maintain
02/11/2017 Broker: Jefferies Rating: Hold New Target: $55.0 Maintain
31/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $60.0 Maintain
31/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $60 New Target: $55 Maintain
19/10/2017 Broker: Loop Capital Rating: Hold Old Target: $61 New Target: $60 Maintain
16/10/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
16/10/2017 Broker: Jefferies Rating: Hold New Target: $65.0 Maintain

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.30, from 1.08 in 2017Q2. It turned negative, as 21 investors sold AMC Networks Inc. shares while 120 reduced holdings. 35 funds opened positions while 75 raised stakes. 53.08 million shares or 0.39% less from 53.29 million shares in 2017Q2 were reported. Vanguard Group Inc reported 4.22M shares. Commercial Bank Of America Corporation De has 716,329 shares. Dean Cap invested 2.05% of its portfolio in AMC Networks Inc. (NASDAQ:AMCX). Ngam Advsr L P invested 0.03% in AMC Networks Inc. (NASDAQ:AMCX). Barclays Public Limited Company invested in 0.01% or 105,428 shares. Morgan Stanley reported 183,418 shares or 0% of all its holdings. Mason Street Advsr Lc holds 25,850 shares or 0.04% of its portfolio. Los Angeles Capital Mgmt Equity Incorporated has 0.01% invested in AMC Networks Inc. (NASDAQ:AMCX) for 41,732 shares. Texas-based Financial Bank has invested 0.67% in AMC Networks Inc. (NASDAQ:AMCX). Benjamin F Edwards & owns 0.02% invested in AMC Networks Inc. (NASDAQ:AMCX) for 2,426 shares. Northwestern Mutual Wealth Management accumulated 0% or 512 shares. Ny State Teachers Retirement System reported 112,900 shares or 0.02% of all its holdings. Origin Asset Management Llp, United Kingdom-based fund reported 5,145 shares. Jefferies Group Incorporated Limited Liability Company has 61,326 shares for 0.02% of their portfolio. First Tru Advsrs Lp stated it has 27,776 shares.

The stock increased 1.84% or $0.95 during the last trading session, reaching $52.54. About 478,260 shares traded. AMC Networks Inc. (NASDAQ:AMCX) has declined 17.50% since February 15, 2017 and is downtrending. It has underperformed by 34.20% the S&P500.

AMC Networks Inc. owns and operates various cable televisionÂ’s brands delivering content to audiences, and a platform to distributors and advertisers in the United States and internationally. The company has market cap of $3.25 billion. The firm operates in two divisions, National Networks; and International and Other. It has a 10.44 P/E ratio. The National Networks segment operates five distributed entertainment programming networks under the AMC, WE tv, BBC AMERICA, IFC, and SundanceTV names in high definition and standard definition formats.

Investors sentiment decreased to 1.73 in 2017 Q3. Its down 2.10, from 3.83 in 2017Q2. It dived, as 13 investors sold Loxo Oncology, Inc. shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. Orbimed Limited Liability accumulated 1.73M shares. The Illinois-based Northern Trust Corp has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Smith Asset Mngmt Gru Inc L P accumulated 4,430 shares or 0.01% of the stock. Rhenman Ptnrs Asset Mngmt Ab reported 75,000 shares. Savings Bank Of America Corporation De has 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 13,769 shares. Jasper Ridge Prtn L P holds 0.02% or 3,457 shares in its portfolio. Cornerstone Cap Mgmt Holdings Limited Liability Corporation has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Foresite Cap Mgmt Ii Limited Liability Company invested 0.53% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Citadel Advisors Limited Liability Corp has invested 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Perigon Wealth Management Ltd holds 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 100 shares. Columbia Wanger Asset Mgmt Limited Liability Company holds 0.73% or 534,279 shares in its portfolio. Sectoral Asset Incorporated holds 2.91% or 245,226 shares in its portfolio. Bvf Il owns 2.79% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 238,386 shares. Fil has invested 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO).

The stock increased 3.40% or $3.43 during the last trading session, reaching $104.35. About 504,068 shares traded or 25.37% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since February 15, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on March, 6. They expect $-1.27 EPS, up 0.78% or $0.01 from last year’s $-1.28 per share. After $-1.12 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts 13.39% negative EPS growth.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $3.12 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>